Regeneron Announces Investor Conference Presentations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)
April 22, 2026 2:56 PM EDTRaymond James analyst Chris Raymond reiterated an Outperform rating and $910.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Remain Outperform rated on REGN shares following the companys Regeneron Roundtable investor event this morning on the C5 complement program. Recall REGN is developing two complementary treatments that target complement factor... More
